Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Year-over-year book value per share growth
Latest
-5.25%
↓ 101% vs avg
Percentile
P54
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
503.77%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -5.25% |
| Q3 2025 | -32.28% |
| Q2 2025 | -17.19% |
| Q1 2025 | -8.21% |
| Q4 2024 | 389.95% |
| Q3 2024 | 245.82% |
| Q2 2024 | 98.49% |
| Q1 2024 | -1391.15% |
| Q4 2023 | -87.92% |
| Q3 2023 | 163.00% |
| Q2 2023 | 6.70% |
| Q1 2023 | 53.86% |
| Q4 2022 | -437.84% |
| Q3 2022 | 65.97% |
| Q2 2022 | -193.81% |
| Q1 2022 | -72.19% |
| Q4 2021 | -49.58% |
| Q3 2021 | 101.81% |
| Q2 2021 | -43.13% |
| Q1 2021 | 15.65% |
| Q4 2020 | -36.38% |
| Q3 2020 | -35.11% |
| Q2 2020 | 77.99% |
| Q1 2020 | 14.48% |
| Q4 2019 | 13.43% |
| Q3 2019 | 2.17% |
| Q2 2019 | -25.50% |
| Q1 2019 | -31.05% |
| Q4 2018 | 7.18% |
| Q3 2018 | -5.54% |
| Q2 2018 | -24.07% |
| Q1 2018 | 21043.40% |
| Q4 2017 | 43.67% |
| Q3 2017 | 162.38% |
| Q2 2017 | 667.14% |
| Q1 2017 | -286.55% |
| Q4 2016 | -66.66% |
| Q3 2016 | -89.59% |
| Q2 2016 | -37.27% |
| Q1 2016 | -45.83% |